Lilach O. Lerman

EBioMedicine · 2019

⊕ Open access · CC-BY

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

▲ 1,359

Nature Reviews Nephrology · 2022

⊕ Open access · OA

Cellular senescence: the good, the bad and the unknown

▲ 1,156

Frontiers in Cell and Developmental Biology · 2020

⊕ Open access · CC-BY

Human Obesity Induces Dysfunction and Early Senescence in Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells

▲ 174

Journal of the American Society of Nephrology · 2021

⊕ Preprint · OA

Progressive Cellular Senescence Mediates Renal Dysfunction in Ischemic Nephropathy

▲ 107

EBioMedicine · 2020

⊕ Open access · CC-BY

Corrigendum to ‘Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease’ EBioMedicine 47 (2019) 446–456

▲ 59

Oxidative Medicine and Cellular Longevity · 2021

⊕ Open access · CC-BY

Quercetin Reverses Cardiac Systolic Dysfunction in Mice Fed with a High‐Fat Diet: Role of Angiogenesis

▲ 55

Frontiers in Endocrinology · 2021

⊕ Open access · CC-BY

Metabolic Syndrome Is Associated With Altered mRNA and miRNA Content in Human Circulating Extracellular Vesicles

▲ 14

EBioMedicine · 2026

⊕ Open access · CC-BY

Senolytics, dasatanib plus quercetin, reduce kidney inflammation, senescent cell abundance, and injury while restoring geroprotective factors in murine diabetic kidney disease

▲ 9

Stem Cells · 2023

⊕ Open access · OA

Mesenchymal Stem/Stromal Cells Therapy for Metabolic Syndrome: Potential Clinical Application?

▲ 8

Kidney International · 2026

⊕ Preprint · OA

Targeting cellular senescence in diabetic kidney disease: potential of regenerative, cell-based therapies and other senotherapeutic approaches

▲ 6